Table 1.

Study characteristics of the included studies.

No	Reference	Country	N patients	Gender (M/F)	Age	KPS	Tumor site	Stage	Follow-up (median or mean)	Arm	Dose/fraction (Gy)	Total dose (Gy)
1	Pan et al. [15]	China	200	150/50	49 (18–70)	≥70	Nasopharynx	I–IV	6.9 years	HART	1.2–1.5	78
										CFRT	2	70
2	Wang et al. [16]	China	98	63/35	65 (55–74)	≥70	Esophageal	—	45 (36–58) months	HART	1.5	64 (61–67)
										CFRT	2	64 (60–68)
3	Dobrowsky and Naude [9]	Ireland	159	139/22	34–77	90–100	Oral cavity Oropharynx Hypopharynx Larynx	T1–T4 N0–N3	48 months	HART	1.65–2.5	55.3
										CFRT	2	70
4	Teo et al. [17]	China	159	122/37	—	—	Nasopharynx	II–IV	59.2 months	HART	1.5	22.4
										CFRT	2.5	20
5	Shi et al. [18]	China	85	50/35	55.6	>70	Esophagus	—	5 years	HART	1.5–1.8	68.4
										CFRT	1.8	68.4
6	Fallai et al. [11]	Italy	128	112/16	—	≥70	Oropharynx	III-IV	8.35 (4.8–10.2) years	HART	1.6	64–67.2
										CFRT	—	66–70
7	Saunders et al. [19]	United Kingdom	918	—	—	—	—	T2–T4 N0-N1 M0	≤6 years	HART	1.5	54
										CFRT	2	66
8	El-Weshi et al. [20]	Egypt	50	40/10	39.9 (18–63)	—	Nasopharynx	III-IV	55 (4–120) months	HART	1.6	72
										CFRT	2	72
9	Miszczyk et al. [21]	Poland	101	78/23	57 (42–73)	—	Excluding nasopharynx	T2N3 T3N03 T4N0-N3	—	HART	1.6	64
										CFRT	2	50
10	Awwad et al. [12]	Egypt	70	56/14	50 (25–65)	—	Oral cavity Hypopharynx Larynx	T2–T4	—	HART	1.4	46.2
										CFRT	2	60
11	Dische et al. [7]	United Kingdom	918	687/231	—	—	Nasal sinus Nasopharynx Oral cavity Oropharynx Hypopharynx Larynx	T1–T4	N0–N3	HART	1.5	54
										CFRT	2	66
12	Bartelink et al. [10]	Netherlands	49	38/11	—	—	Oral cavity Oropharynx Larynx Hypopharynx	T2–T4	—	HART	1.6	72
										CFRT	2	70

Notes: “–,” not mentioned. CFRT, conventional fractionation radiotherapy; HART, accelerated hyperfractionated radiotherapy.